BRAF基因属于RAF基因家族,该家族包括ARAF、BRAF和CRAF(RAF1),它们编码丝氨酸/苏氨酸蛋白激酶,参与调控MAPK/ERK信号通路(细胞生长、分化和存活的關鍵通路)。BRAF基因位于人类7号染色体(7q34),编码的BRAF蛋白通过磷酸化MEK1/2激活下游ERK信号。BRAF最常见的突变是V600E(第600位缬氨酸被谷氨酸取代),导致激酶活性持续激活,引发MAPK通路异常信号传导。这种突变与多种癌症相关,如黑色素瘤(约50%病例)、甲状腺乳头状癌(45%)、结直肠癌(10%)和少数肺癌。BRAF突变还可能导致罕见发育障碍如努南综合征(Noonan syndrome)和心-面-皮肤综合征(Cardio-facio-cutaneous syndrome)。当BRAF过表达时,会过度激活MAPK通路,促进细胞增殖和肿瘤发生;而表达降低可能导致发育缺陷或细胞凋亡增加。针对BRAF V600E的靶向药物如维莫非尼(vemurafenib)和达拉非尼(dabrafenib)已用于临床,但长期使用可能引发耐药性(如通过MEK或NRAS突变)。野生型BRAF在神经发育和血管形成中起重要作用,而突变体可能通过"激酶活性依赖"或"非依赖"机制(如改变蛋白相互作用)影响细胞行为。BRAF抑制剂常与MEK抑制剂(如曲美替尼trametinib)联用以延缓耐药。需要注意的是,某些BRAF突变(如D594G)反而会降低激酶活性,但可能通过激活CRAF间接促进肿瘤。
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008]
该基??因编码属于RAF / MIL家庭丝氨酸/苏氨酸蛋白激酶的蛋白质。这种蛋白质在调节MAP激酶/ ERK的信号传导途径,从而影响细胞分裂,分化,和分泌的作用。在这个基因的突变与心脸皮肤综合征,这种疾病的特点是心脏畸形,智力低下及鲜明的面容有关。在这个基因的突变也已与各种癌症,包括非何杰金氏淋巴瘤,结肠直肠癌,恶性黑素瘤,甲状腺癌,非小细胞肺癌和肺腺癌相关联。假基因,位于X染色体上,已经确定了这个基因。 [由RefSeq的,2008年7月提供]
BRAF基因(以及对应的蛋白质)的细胞分布位置:
BRAF基因的本体(GO)信息:
名称 |
---|
4015 Rap1 signaling pathway [PATH:hsa04015] |
4010 MAPK signaling pathway [PATH:hsa04010] |
4012 ErbB signaling pathway [PATH:hsa04012] |
4068 FoxO signaling pathway [PATH:hsa04068] |
4024 cAMP signaling pathway [PATH:hsa04024] |
4150 mTOR signaling pathway [PATH:hsa04150] |
4810 Regulation of actin cytoskeleton [PATH:hsa04810] |
4510 Focal adhesion [PATH:hsa04510] |
4650 Natural killer cell mediated cytotoxicity [PATH:hsa04650] |
4062 Chemokine signaling pathway [PATH:hsa04062] |
4910 Insulin signaling pathway [PATH:hsa04910] |
4914 Progesterone-mediated oocyte maturation [PATH:hsa04914] |
4270 Vascular smooth muscle contraction [PATH:hsa04270] |
4726 Serotonergic synapse [PATH:hsa04726] |
4720 Long-term potentiation [PATH:hsa04720] |
4730 Long-term depression [PATH:hsa04730] |
4722 Neurotrophin signaling pathway [PATH:hsa04722] |
5200 Pathways in cancer [PATH:hsa05200] |
5205 Proteoglycans in cancer [PATH:hsa05205] |
5210 Colorectal cancer [PATH:hsa05210] |
5212 Pancreatic cancer [PATH:hsa05212] |
5214 Glioma [PATH:hsa05214] |
5216 Thyroid cancer [PATH:hsa05216] |
5221 Acute myeloid leukemia [PATH:hsa05221] |
5220 Chronic myeloid leukemia [PATH:hsa05220] |
5218 Melanoma [PATH:hsa05218] |
5211 Renal cell carcinoma [PATH:hsa05211] |
5219 Bladder cancer [PATH:hsa05219] |
5215 Prostate cancer [PATH:hsa05215] |
5213 Endometrial cancer [PATH:hsa05213] |
5223 Non-small cell lung cancer [PATH:hsa05223] |
5034 Alcoholism [PATH:hsa05034] |
5160 Hepatitis C [PATH:hsa05160] |
名称 |
---|
Activation of NMDA receptor upon glutamate binding and postsynaptic events |
ARMS-mediated activation |
CREB phosphorylation through the activation of Ras |
Frs2-mediated activation |
Negative regulation of FGFR1 signaling |
Negative regulation of FGFR2 signaling |
Negative regulation of FGFR3 signaling |
Negative regulation of FGFR4 signaling |
Neuronal System |
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell |
NGF signalling via TRKA from the plasma membrane |
Post NMDA receptor activation events |
Prolonged ERK activation events |
Signal Transduction |
Signaling by FGFR |
Signaling by FGFR1 |
Signaling by FGFR2 |
Signaling by FGFR3 |
Signaling by FGFR4 |
Signalling by NGF |
Signalling to ERKs |
Signalling to p38 via RIT and RIN |
Spry regulation of FGF signaling |
Transmission across Chemical Synapses |
疾病名称 | 关系值 | NofPmids | NofSnps | 来源 |
Cardio-facio-cutaneous syndrome | 0.567057489 | 30 | 29 | BeFree_CLINVAR_CTD_human_MGD_ORPHANET_UNIPROT |
melanoma | 0.430771416 | 851 | 6 | BeFree_CLINVAR_CTD_human_GAD_LHGDN |
NOONAN SYNDROME 7 | 0.36 | 2 | 14 | CLINVAR_CTD_human_UNIPROT |
LEOPARD SYNDROME 3 | 0.36 | 1 | 1 | CLINVAR_CTD_human_UNIPROT |
Papillary thyroid carcinoma | 0.324734064 | 348 | 3 | BeFree_CLINVAR_GAD_ORPHANET |
Thyroid Neoplasm | 0.288143256 | 101 | 1 | BeFree_CTD_human_GAD_LHGDN |
Colorectal Cancer | 0.274375073 | 298 | 2 | BeFree_GAD_UNIPROT |
Noonan Syndrome | 0.248458305 | 9 | 0 | BeFree_CTD_human_GAD_ORPHANET |
Adenocarcinoma of lung (disorder) | 0.243528744 | 13 | 3 | BeFree_CLINVAR_CTD_human |
Lymphoma, Non-Hodgkin | 0.242367032 | 3 | 3 | CLINVAR_GAD_UNIPROT |
关注微信订阅号,实时查看信息,关注医学生物学动态。